Strongbridge Biopharma plc

Strongbridge Biopharma — Merger or Acquisition (May 2021)

22 slides from Strongbridge Biopharma's merger presentation, May 24, 2021

  1. Slide 1: Report on Merger Benefit Statement

    The Directors Xeris Pharmaceuticals, Inc. 180 North LaSalle Street Suite 1600 Chicago, IL 60601 USA SVB Leerink LLC 227 W. Trade Street, Suite 2050 Charlotte, NC 28202 USA 24 May 2021 Dear Sir or Madam: Report on Merger Benefit statement We refer to the Merger Benefit Statement (the ‘Statement’) mad

  2. Slide 2: Xeris to Acquire Strongbridge Creating an Innovative Leader in Endocrinology and Rare Diseases

    Xeris to Acquire Strongbridge Creating an Innovative Leader in Endocrinology and Rare Diseases May 24, 2021 Exhibit 99.3

  3. Slide 3: No Offer or Solicitation; Additional Information

    The announcement issued jointly by Xeris and Strongbridge under Rule 2.5 of the Irish Takeover Rules on May 24, 2021 (the “Rule 2.5 Announcement”) is available on Xeris’ website at www.xerispharma.com and on Strongbridge’s website at www.strongbridgebio.com. Appendix I to the Rule 2.5 Announcement c

  4. Slide 4: Forward-Looking Statements

    FORWARD-LOOKING STATEMENTS This communication contains certain forward-looking statements with respect to a proposed transaction involving Xeris and Strongbridge and Xeris’, Strongbridge’s and/or the combined group’s estimated or anticipated future business, performance and results of operations and

  5. Slide 5: No Profit Forecast / Asset Valuations

    No Profit Forecast / Asset Valuations No statement in this communication is intended to constitute a profit forecast for any period, nor should any statements be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financ

  6. Slide 6: Presenters

    Presenters Paul R. Edick Xeris Pharmaceuticals Chairman and CEO John H. Johnson Strongbridge Biopharma plc CEO

  7. Slide 7: Diversified and Increased Revenue Growth Expected

    Diversified and Increased Revenue Growth Expected: Stronger revenue base with growing commercial assets - Gvoke® and KEVEYIS® – presence in markets with large addressable market plus potential. Opportunity for rapid launch of RECORLEV, if approved by FDA, leveraging Xeris’ experienced, endocrinology

  8. Slide 8: Transaction Overview

    Transaction Overview Terms All-stock transaction, values Strongbridge at ~$267 million Each Strongbridge ordinary share to be converted into 0.7840 shares of Xeris Biopharma Holdings common stock (~$2.72 per share) Strongbridge shareholders will receive 1 non-tradeable Contingent Value Right for eac

  9. Slide 9: Combining Two Innovators in Endocrinology and Rare Diseases

    Combining Two Innovators in Endocrinology and Rare Diseases Xeris’ technology capabilities and experienced leadership team will be complemented by the addition of Strongbridge’s commercial and development infrastructure to drive growth Focused on ready-to-use injectable and infusible drug formulatio

  10. Slide 10: Two Fast-Growing Branded Products in Market

    Two Fast-Growing Branded Products in Market 1. Charles G, Zheng C, Lehmann-Horn F, Jurkatt-Rott, Levitt J. Characterization of hyperkalemic periodic paralysis: a survey of genetically diagnosed individuals. J Neurol. 2013;260:2606-2613. 2. Cannon SC. Channelopathies of skeletal muscle excitability.

  11. Slide 11: Gvoke Market Opportunity

    Gvoke Market Opportunity All persons on insulin should have a glucagon tool they have confidence in Many people who would be clinically appropriate for a glucagon prescription never have it available1,2 People with T2D on insulin (est) Total glucagon prescription filled Few prescriptions are written

  12. Slide 12: RECORLEV Commercial Opportunity

    RECORLEV Commercial Opportunity Treats Endogenous Cushing’s syndrome, which is a serious rare disease that affects the whole body * Source: Based on Strongbridge Biopharma plc research ** Source: Secondary literature and company sponsored research *** A07. Of your endogenous Cushing’s patients curre

  13. Slide 13: Xeris Technology Platforms Have Potential for Broad Application

    Xeris Technology Platforms Have Potential for Broad Application Two types of novel formulations create potential to be utilized across range of endocrinology and other therapeutic areas Platforms Biocompatible non-aqueous injectable solutions or suspensions can be packaged for administration in vari

  14. Slide 14: Strong Pipelines with High Potential Value

    Strong Pipelines with High Potential Value Pipeline includes products across the range of development, reflecting several potential value creation inflection points and a healthy runway for growth over the long-term †Orphan Drug Designation *Fast Track Designation Product Candidate Indication Develo

  15. Slide 15: Experienced Commercial and Development Teams and Shared Patient-Centric Culture

    Experienced Commercial and Development Teams and Shared Patient-Centric Culture Combined company will have robust endocrinology and rare disease-focused commercial and development infrastructure to bring product benefits to a wider range of patients Combined company’s highly experienced commercial s

  16. Slide 16: Q1 Snapshot and Significant Potential Synergies

    Q1 Snapshot and Significant Potential Synergies $8.1M Net sales of Gvoke 380% Revenue growth achieved with Gvoke vs. Q1 prior year $8.4M Net sales of KEVEYIS $73.9M of cash and cash equivalents as of March 31, 2021 $135.9M of cash, cash equivalents and investments as of March 31, 2021 25% Revenue gr

  17. Slide 17: Strong Intellectual Property Rights Across Products

    Strong Intellectual Property Rights Across Products 117 total patents globally, of which 14 are U.S. issued 96 patent applications pending globally, of which 15 are pending in the U.S. 2036 Glucagon protection out to 2036 Combined company will continue to take Xeris’ successful approach of patenting

  18. Slide 18: Roadmap to Close

    Roadmap to Close Unanimously approved by Xeris and Strongbridge Boards, (with exception of Jeff Sherman, common director of both companies, who abstained from voting) Expected to close in early Q4 2021 Subject to approval from shareholders of both companies and receipt of customary regulatory and go

  19. Slide 19: Diversified and Increased Revenue Growth Expected

    Diversified and Increased Revenue Growth Expected: Stronger revenue base with growing commercial assets - Gvoke® and KEVEYIS® - presence in markets with large addressable market plus potential. Opportunity for rapid launch of RECORLEV, if approved by FDA, leveraging Xeris’ experienced, endocrinology

  20. Slide 20: <x Se) O’

    <x Se) O’

  21. Slide 21: é xXerlS Me cntinee

    é xXerlS Me cntinee PHARMACEUTICALS BIOPHARMA

  22. Slide 22: Rule 2.5 Announcement; No Offer or Solicitation

    The announcement issued jointly by Xeris and Strongbridge under Rule 2.5 of the Irish Takeover Rules on May 24, 2021 (the “ Rule 2.5 Announcement ”) is available on Xeris’ website at www.xerispharma.com and on Strongbridge’s website at www.strongbridgebio.com. Appendix I to the Rule 2.5 Announcement

Strongbridge Biopharma — Merger or Acquisition (May 2021) on 6ix